TransMedics faces securities fraud lawsuit
Analysis based on 7 articles · First reported Feb 26, 2025 · Last updated Apr 10, 2025
The market is negatively impacted by the allegations of fraud and unsafe practices against TransMedics, leading to a significant drop in TransMedics' stock price. This event highlights increased regulatory risk for companies in the medical device industry.
Faruqi & Faruqi, a national securities law firm, is investigating and leading a federal securities class action lawsuit against TransMedics. The lawsuit alleges that TransMedics engaged in kickbacks, fraudulent overbilling, coercive tactics, and unsafe practices, while also hiding safety issues and lacking proper oversight. These allegations stem from a report issued by Scorpion Capital on January 10, 2025, which described TransMedics' business model as an 'extreme and grotesque healthcare fraud.' Following the report, TransMedics' stock fell 5.15% on January 10, 2025, and an additional 6.9% on January 13, 2025. Investors who suffered losses between February 23, 2023, and January 10, 2025, are encouraged to contact Faruqi & Faruqi, with a deadline of April 15, 2025, to seek the role of lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard